Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2005

View Archived Issues

European CE Mark for AlzheimAlert test kit

Phase I program begins for HCV-796

4SC and Sanwa Kagaku Kenkyusho establish drug development collaboration

REN-850 enters phase Ia study for MS

Phase III Insegia study fails to meet primary endpoint

Private financing will fund Jerini's icatibant development

Vertex licenses VX-944 to Avalon for cancer

Enrollment targets met in two phase II studies of squalamine for AMD

Successful launch for Familion test

CTI-01 enters phase II study

Orphan drug designation for INO-1001

Seattle Genetics and CuraGen expand antibody-drug conjugate collaboration

Adherex updates program progress

Positive phase II interim results for talabostat in metastatic melanoma

NIH funding for development of protease inhibitors for orthopoxvirus infections

African program begins for Calypte's Aware rapid HIV-1/2 test platform

NV-1020 reported safe in patients with hepatic colorectal metastases

Promising effects reported for 131I-labetuzumab in colorectal cancer patients with liver metastases

Good safety profile found for E-7070 plus irinotecan in cancer patients

Update on the antitumor effects of NPI-0052 in colorectal cancer

Antitumor efficacy of temsirolimus in neuroendocrine carcinomas

Pfizer claims new cannabinoid CB1 receptor antagonists for obesity

Novel PPAR ligands jointly disclosed by Fujisawa and Daicel

New serotonin 5-HT1B receptor antagonists identified at Pfizer

Six series of phosphatidylinositol 3-kinase inhibitors and their use reported by Pfizer

Phase I study of NMI-861, a combined yohimbine/L-arginine treatment for male erectile dysfunction

Effects of FK-419, a GPIIb/IIIa antagonist, in a model of ischemic brain injury

Cytotoxic activity of HMN-176 in an array of human tumor specimens

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...